An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 15 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Aug 2017 Results published in the Journal of Clinical Oncology.